Ftse Mib
36.133,06
-0,03%
DAX
20.968,65
-0,17%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
102.219,56
0,19%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Autolus Therapeutics PLC (AUTL) Autolus Therapeutics PLC (AUTL) Notizie

AUTL

Autolus Therapeutics (AUTL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AUTL
DataOraFonteTitoloSimboloCompagnia
17/01/202513:00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem MeetingsNASDAQ:AUTLAutolus Therapeutics PLC
13/01/202513:00GlobeNewswire Inc.Autolus Therapeutics Provides Business Updates and 2025 OverviewNASDAQ:AUTLAutolus Therapeutics PLC
10/12/202401:30GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/12/202413:00GlobeNewswire Inc.Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of MedicineNASDAQ:AUTLAutolus Therapeutics PLC
14/11/202422:32Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
14/11/202422:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AUTLAutolus Therapeutics PLC
12/11/202422:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUTLAutolus Therapeutics PLC
12/11/202413:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
12/11/202413:00GlobeNewswire Inc.Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
08/11/202422:23GlobeNewswire Inc.Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)NASDAQ:AUTLAutolus Therapeutics PLC
05/11/202415:00GlobeNewswire Inc.Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster PresentationsNASDAQ:AUTLAutolus Therapeutics PLC
28/10/202422:00GlobeNewswire Inc.Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:AUTLAutolus Therapeutics PLC
25/10/202422:01Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
16/10/202415:00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma CongressNASDAQ:AUTLAutolus Therapeutics PLC
19/09/202413:00GlobeNewswire Inc.Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development OfficerNASDAQ:AUTLAutolus Therapeutics PLC
16/09/202423:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AUTLAutolus Therapeutics PLC
27/08/202413:00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024NASDAQ:AUTLAutolus Therapeutics PLC
08/08/202413:00GlobeNewswire Inc.Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
26/07/202413:00GlobeNewswire Inc.Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024NASDAQ:AUTLAutolus Therapeutics PLC
14/06/202413:00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
31/05/202414:00GlobeNewswire Inc.Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
17/05/202413:00GlobeNewswire Inc.Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202415:33Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202413:00GlobeNewswire Inc.Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallNASDAQ:AUTLAutolus Therapeutics PLC
24/04/202416:00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202413:00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202413:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202413:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202412:00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202412:00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AUTL

La tua Cronologia

ASX
STKOA
Strickland Metals
TG
BMW3
Bayerische Motoren Werke
LSE
0VPX
Ishares Swiss Domestic G...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network